Achieve Life Sciences Inc (OQ:ACHV)

Business Focus: Biotechnology & Medical Research

Mar 28, 2024 04:01 pm ET
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end...
Mar 20, 2024 08:00 am ET
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that three oral presentations...
Mar 14, 2024 08:00 am ET
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its fourth...
Mar 08, 2024 08:35 am ET
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held March 7th are now available for online viewing. This event was sponsored by Zacks...
Mar 06, 2024 08:00 am ET
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will...
Mar 05, 2024 08:35 am ET
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held March 7th. This event is sponsored by Zacks Small-Cap Research. Individual investors,...
Feb 29, 2024 08:01 am ET
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has reached agreement...
Feb 29, 2024 08:00 am ET
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into a...
Dec 15, 2023 08:35 am ET
Life Science Investor Forum: Presentations Now Available for Online Viewing
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Investor Forum sponsored by Zacks Small-Cap Research. held December 14th are now available for online viewing....
Dec 13, 2023 08:00 am ET
TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors
TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the...
Dec 12, 2023 01:02 pm ET
Life Science Investor Forum Agenda Announced for December 14th, 2023
Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held December 14th. This event is sponsored by Zacks Small-Cap Research. Individual investors,...
Dec 12, 2023 08:31 am ET
Thinking about buying stock in Advanced Micro Devices, Palo Alto Networks, Gaotu Techedu, Achieve Life Sciences, or Clearmind Medicine?
NEW YORK, Dec. 12, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, PANW, GOTU, ACHV, and CMND.
Dec 11, 2023 04:30 pm ET
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will...
Nov 09, 2023 04:00 pm ET
Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced third quarter 2023 financial...
Oct 26, 2023 08:00 am ET
Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its...
Oct 03, 2023 08:00 am ET
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that management will be...
Sep 11, 2023 08:00 am ET
Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Phase 2 ORCA-V1...
Sep 07, 2023 08:00 am ET
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of...
Aug 14, 2023 04:00 pm ET
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter 2023 financial...
Aug 01, 2023 08:00 am ET
Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its...
Jul 18, 2023 08:00 am ET
Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced participation on a panel...
Jul 11, 2023 11:23 am ET
Achieve Life Sciences Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)
Achieve Life Sciences, Inc. (NASDAQ: ACHV), today announced the publication in JAMA of the results from the Phase 3 ORCA-2 randomized placebo-controlled clinical trial of cytisinicline as a treatment for smoking cessation, the first large trial of...
Jun 06, 2023 08:00 am ET
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of...
May 25, 2023 09:00 am ET
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into a...
May 23, 2023 06:00 am ET
Achieve Life Sciences Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced positive topline results from...
May 17, 2023 08:00 am ET
Achieve Life Sciences Announces Refinancing of Outstanding Loan with Silicon Valley Bank
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced the Company has refinanced its...
May 09, 2023 04:05 pm ET
Achieve Life Sciences Reports Financial Results for First Quarter 2023 and Provides Corporate Update
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced first quarter 2023 financial...
Apr 26, 2023 08:00 am ET
Achieve Life Sciences to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 9, 2023
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its...
Apr 20, 2023 08:00 am ET
Achieve Life Sciences Announces Positive Phase 2 ORCA-V1 Trial Results Showing Statistically Significant Vaping Cessation Benefit for Participants Treated with Cytisinicline
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today reported positive topline results from...
Apr 14, 2023 08:00 am ET
Achieve Life Sciences to Present at Life Science Innovation Northwest 2023 Conference
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of...
Mar 30, 2023 08:00 am ET
Achieve Life Sciences Announces Refresh to Board of Directors
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced changes to the Company’s Board...
Mar 29, 2023 08:00 am ET
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the last study follow-up...
Mar 17, 2023 08:00 am ET
Achieve Life Sciences Announces Granting of New Hire Inducement Award
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the Company has issued an...
Mar 16, 2023 04:05 pm ET
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and...
Mar 08, 2023 08:00 am ET
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the last study...
Mar 03, 2023 08:00 am ET
Achieve Life Sciences Announces Presentation of the Phase 3 ORCA-2 Trial of Cytisinicline at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced data from the Phase 3...
Mar 02, 2023 08:00 am ET
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2022 Financial Results and Host Conference Call and Webcast on March 16, 2023
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its...
Feb 07, 2023 08:00 am ET
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the final subject...
Feb 02, 2023 08:00 am ET
Achieve Life Sciences to Participate at the 2023 SVB Securities Global Biopharma Conference
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will participate in...
Jan 27, 2023 04:30 pm ET
Achieve Life Sciences Announces Granting of New Hire Inducement Award
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued an...
Jan 09, 2023 08:00 am ET
Achieve Life Sciences Announces Last Subject Dosed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the final...
Dec 21, 2022 08:00 am ET
Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that the United States...
Nov 15, 2022 08:00 am ET
Achieve Life Sciences Announces Private Placement of $18.9 Million
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered...
Nov 14, 2022 04:05 pm ET
Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced third quarter 2022...
Nov 08, 2022 08:00 am ET
Achieve Announces Early Completion of Target Enrollment in Cytisinicline e-Cigarette Cessation Trial
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for nicotine dependence, today announced that target enrollment has been reached in...
Oct 31, 2022 08:00 am ET
Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 14, 2022
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its...
Sep 27, 2022 08:00 am ET
Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that target...
Sep 07, 2022 08:00 am ET
Achieve Life Sciences Announces Participation at Fall Investor Conferences
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be...
Aug 11, 2022 04:05 pm ET
Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2022...
Jul 28, 2022 08:00 am ET
Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11, 2022
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its...
Jul 01, 2022 04:05 pm ET
Achieve Life Sciences Announces Granting of New Hire Inducement Awards
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has issued...
Jun 29, 2022 08:00 am ET
Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine e-cigarette Cessation
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening of...
Jun 21, 2022 08:00 am ET
Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be...
Jun 01, 2022 08:00 am ET
Achieve Life Sciences Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine e-cigarette Users
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has been...
May 26, 2022 08:00 am ET
Achieve Life Sciences Announces Participation at LD Micro Invitational Conference
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at...
May 16, 2022 01:20 pm ET
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.
May 13, 2022 08:00 am ET
Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating at...
May 12, 2022 04:00 pm ET
Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2022...
Apr 27, 2022 10:01 am ET
Thinking about buying stock in Agile Therapeutics, Constellium SE, Achieve Life Sciences, Alliance Resource Partners, or Nordic American Tanker?
NEW YORK, April 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AGRX, CSTM, ACHV, ARLP, and NAT.
Apr 27, 2022 08:00 am ET
Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers
Achieve Life Sciences, Inc. (NASDAQ: ACHV), today announced positive topline results from the Phase 3 ORCA-2 trial of cytisinicline. ORCA-2 was designed to evaluate the efficacy and safety of 3mg cytisinicline dosed 3 times daily for a period of...
Apr 21, 2022 08:00 am ET
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 12, 2022
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its first...
Mar 15, 2022 08:00 am ET
Achieve Life Sciences Announces Cytisinicline Presentation at Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a presentation on...
Mar 14, 2022 08:00 am ET
Achieve Life Sciences Announces Appointment of Dr. Vaughn Himes to Board of Directors
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of...
Mar 11, 2022 08:00 am ET
Achieve Life Sciences Announces Expansion of Manufacturing & Quality Operations Team and Granting of Inducement Award
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has...
Mar 10, 2022 08:00 am ET
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2021 and Provides Corporate Update
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end...
Mar 08, 2022 08:00 am ET
Achieve Life Sciences Announces Participation in March Investor Conferences
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating in...
Feb 24, 2022 08:00 am ET
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2021 Financial Results and Host Conference Call and Webcast on March 10, 2022
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will report its fourth...
Feb 03, 2022 08:00 am ET
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Award
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has...
Feb 02, 2022 08:00 am ET
Achieve Life Sciences Announces Participation in February Investor Conferences
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be participating in...
Jan 28, 2022 10:07 am ET
36 of the Best Ideas Companies to Present at the 2nd Annual Winter Wonderland Virtual Investor Conference on February 8th - 11th, 2022
RALEIGH, NC / ACCESSWIRE / January 28, 2022 / The Winter Wonderland Best Ideas Virtual Investor Conference will take place on February 8th - 11th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience.
Jan 25, 2022 08:00 am ET
Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it has initiated screening...
Jan 06, 2022 08:30 am ET
Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief...
Jan 04, 2022 08:30 am ET
Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the last study...
Dec 22, 2021 08:30 am ET
Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cessation Clinical Development
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a...
Nov 23, 2021 08:30 am ET
Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the Company will host a...
Nov 22, 2021 08:30 am ET
Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the completion of the fifth...
Nov 09, 2021 04:05 pm ET
Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development
-- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced third quarter 2021...
Nov 04, 2021 08:30 am ET
Achieve Life Sciences Announces Participation in November Investor Conferences
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that its management team...
Nov 02, 2021 08:30 am ET
Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline’s Second Planned Indication for Nicotine E-cigarette Cessation
-- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the U.S. Food and...
Oct 26, 2021 08:30 am ET
Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its...
Sep 15, 2021 05:30 am ET
Achieve Life Sciences to Participate in Upcoming Investor Conferences
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will participate in two upcoming investor conferences.
Sep 14, 2021 05:30 am ET
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that cytisinicline data will be presented at two sessions during the upcoming Society for Research on Nicotine & Tobacco (SRNT-E) Conference to be held virtually September 15-17, 2021.
Sep 09, 2021 05:30 am ET
Achieve Life Sciences to Participate in Two Upcoming Investor Conferences
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 9, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will be participating in two upcoming investor conferences.
Aug 13, 2021 05:30 am ET
Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations, a Senior Manager of Clinical Trials, and a Senior Director of Biometrics.
Aug 11, 2021 04:05 pm ET
Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2021 financial results and provided an update on the cytisinicline clinical development program.
Aug 11, 2021 05:30 am ET
Achieve Announces Two Patents Granted by USPTO for Novel Cytisinicline Dosing and Administration Regimen
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,083,715 and U.S. Patent No. 11,083,716 covering the novel 3.0 mg three times daily (TID) cytisinicline dosing regimen.
Aug 03, 2021 05:30 am ET
Achieve Life Sciences to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 12, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / August 3, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its second quarter 2021 financial results and provide an update on the cytisinicline development program on Thursday, August 12, 2021 at 4:30PM EDT.
Jul 22, 2021 09:35 am ET
Achieve Life Sciences Awarded Grant from the National Institutes of Health (NIH) for the Evaluation of Cytisinicline in Cessation of Nicotine E-cigarette Use
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / July 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has been awarded a grant from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH) to evaluate the use of cytisinicline as a treatment for cessation of nicotine e-cigarette use.
Jun 29, 2021 05:30 am ET
Achieve Announces Completion of Target Enrollment of 750 Subjects in Phase 3 ORCA-2 Smoking Cessation Trial of Cytisinicline
ORCA-2 Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States
Jun 03, 2021 05:30 am ET
Achieve Announces Allowance of U.S. Patents for Dosing and Administration of Cytisinicline for the Treatment and Prevention of Addiction
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / June 3, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the United States Patent and Trademark Office has allowed U.S. Patent Application No. 16/993,522 (the ‘522 Application) and U.S. Patent Application No. 17/101,686 (the ‘686 Application) covering the novel 3.0 mg three times daily (TID) cytisinicline dosing regimen.
Jun 02, 2021 05:30 am ET
Achieve Life Sciences to Present at LD Micro Invitational XI Virtual Conference
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / June 2, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the company will be participating in the LD Micro Invitational XI Conference, being held virtually from June 8-10, 2021. John Bencich, Chief Executive Officer, is scheduled to host a virtual presentation on Wednesday, June 9, 2021, at 2:30 p.m. EDT.
May 27, 2021 04:05 pm ET
Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 27, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of its underwritten public offering of 3,285,714 shares of its common stock at a public offering price of $7.00 per share, which includes 428,571 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. The gross proceeds from the offe
May 25, 2021 08:30 am ET
Achieve Life Sciences Announces Pricing of $20 Million Underwritten Public Offering
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 25, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 2,857,143 shares of its common stock at a price to the public of $7.00 per share. Achieve has also granted the underwriters a 30-day option to purchase up to an additional 428,571 shares of common stock in connection with the public offering. All of the securitie
May 24, 2021 04:05 pm ET
Achieve Life Sciences Announces Proposed Underwritten Public Offering
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 24, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock. In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the securities are be
May 13, 2021 04:05 pm ET
Achieve Reports Financial Results for First Quarter 2021 and Provides Corporate Update
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 13, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2021 financial results and provided an update on the cytisinicline clinical development program.
May 04, 2021 05:30 am ET
Achieve Life Sciences to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / May 4, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its first quarter 2021 financial results and provide an update on the cytisinicline development program on Thursday, May 13, 2021 at 4:30PM EDT.
Apr 22, 2021 05:30 am ET
Achieve Life Sciences, Inc. to Host Virtual Non-Deal Roadshow on Tuesday, April 27, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / April 22, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it will be hosting a Virtual Non-Deal Roadshow on Tuesday, April 27, 2021, at 9:00AM EDT. Achieve's Chief Executive Officer, John Bencich, will be providing a corporate presentation and participating in a Q&A session with John Vandermosten, Senior Biotech Analyst at Zacks Small Cap Research.
Apr 14, 2021 05:30 am ET
Achieve Announces Publication of the ORCA-1 Phase 2b Clinical Trial of Cytisinicline in Adult Smokers in Nicotine and Tobacco Research
Cytisinicline Up to Five Times More Likely to Result in Smoking Abstinence Compared to Placebo
Mar 25, 2021 05:30 am ET
Achieve Announces Publication of the RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix(R) (varenicline) in Addiction
Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline
Mar 16, 2021 05:30 am ET
Achieve Life Sciences to Participate in M-Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer Products
Mar 15, 2021 06:30 am ET
Achieve Life Sciences Announces Appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to Board of Directors
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, is pleased to announce the appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to the company's Board of Directors, effective immediately.
Mar 11, 2021 04:05 pm ET
Achieve Reports Financial Results for Fourth Quarter and Year-End 2020 and Provides Corporate Update
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2020 financial results and provided an update on the cytisinicline clinical development program.
Mar 04, 2021 05:30 am ET
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call and Webcast on March 11, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 4, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its fourth quarter and year-end 2020 financial results and provide an update on the cytisinicline development program on Thursday, March 11, 2021 at 4:30 PM ET.
Feb 24, 2021 06:30 am ET
Achieve Life Sciences Announces Presentation of Data on Smoker and E-Cigarette User Attitudes and Perceptions on Quitting at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / February 24, 2021 / Achieve Life Sciences, Inc. (Nasdaq:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that three posters featuring data on smoker and e-cigarette user behavior will be presented today, Wednesday, February 24th at the SRNT Annual Meeting being held virtually. An overview of the data can be also accessed by visiting https://ir.achievel
Feb 11, 2021 08:00 am ET
Achieve Life Sciences to Present at the MicroCap Rodeo Winter Wonderland Conference on February 16, 2021
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / February 11, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will present at the MicroCap Rodeo Winter Wonderland Conference, which is being held virtually on February 16th - 19th, 2021.
Jan 07, 2021 05:30 am ET
Achieve Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference being held virtually January 11-14, 2021.
Dec 07, 2020 03:05 pm ET
Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
SEATTLE and VANCOUVER, B.C., Dec. 7, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of an underwritten public offering of 2,472,500 shares of its common stock at a public offering price of $7.00, for total  gross proceeds of $17.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. This includes the full exercise of the underwriter's over-allotment
Dec 07, 2020 03:05 pm ET
Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
SEATTLE and VANCOUVER, B.C., Dec. 7, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of an underwritten public offering of 2,472,500 shares of its common stock at a public offering price of $7.00, for total  gross proceeds of $17.3 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. This includes the full exercise of the underwriter's over-al
Dec 03, 2020 07:00 am ET
Achieve Life Sciences Announces Pricing of $15 Million Public Offering
SEATTLE and VANCOUVER, B.C., Dec. 3, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 2,150,000 shares of its common stock at a price to the public of $7.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other offering expenses payable by Achie
Dec 03, 2020 07:00 am ET
Achieve Life Sciences Announces Pricing of $15 Million Public Offering
SEATTLE and VANCOUVER, B.C., Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 2,150,000 shares of its common stock at a price to the public of $7.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $15 million, before deducting underwriting discounts and commissions and other offering expenses payable b
Nov 30, 2020 06:00 am ET
Achieve Life Sciences Announces Proposed Public Offering
SEATTLE and VANCOUVER, BC, Nov. 30, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell 1,500,000 shares of its common stock. In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to an additional 225,000 shares of common stock offered in the public offering.  All of the securities are being offered by A
Nov 30, 2020 06:00 am ET
Achieve Life Sciences Announces Proposed Public Offering
SEATTLE and VANCOUVER, BC, Nov. 30, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell 1,500,000 shares of its common stock. In addition, Achieve intends to grant the underwriters a 30-day option to purchase up to an additional 225,000 shares of common stock offered in the public offering.  All of the securities are being offer
Nov 12, 2020 03:05 pm ET
Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update
SEATTLE and VANCOUVER, BC, Nov. 12, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced third quarter 2020 financial results and provided an update on the cytisinicline clinical development program.
Nov 12, 2020 03:05 pm ET
Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update
SEATTLE and VANCOUVER, BC, Nov. 12, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced third quarter 2020 financial results and provided an update on the cytisinicline clinical development program.
Oct 29, 2020 05:30 am ET
Achieve Life Sciences to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
SEATTLE and VANCOUVER, BC, Oct. 29, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its third quarter 2020 financial results and provide an update on the cytisinicline development program on Thursday, November 12, 2020 at 4:30PM ET.
Oct 27, 2020 05:30 am ET
Achieve Life Sciences to Host Smoking Cessation Key Opinion Leader Virtual Roundtable on November 17th, 2020
SEATTLE and VANCOUVER, BC, Oct. 27, 2020 /PRNewswire/ --Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the Company will host a Key Opinion Leader (KOL) virtual roundtable event on cytisinicline and smoking cessation on Tuesday, November 17th, 2020, at 12:00PM EST. 
Oct 08, 2020 06:30 am ET
Achieve Life Sciences Announces to Present at the MicroCap Best Ideas Conference, October 13, 2020
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / October 8, 2020 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held virtually October 13th - 16th, 2020.
Sep 30, 2020 08:00 am ET
Achieve Life Sciences Announces Appointment of John Bencich to Chief Executive Officer & Dr. Cindy Jacobs to President
SEATTLE and VANCOUVER, BC, Sept. 30, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the promotion of John Bencich to Chief Executive Officer. Mr. Bencich has been serving as Achieve's Chief Financial and Operating Officer since 2017. Mr. Bencich will join the Board of Directors in his role as Chief Executive Officer. Rick Stewart, Achieve's current Chairman and Chief Executive Officer, will remain with Achieve as the Executive Ch
Aug 06, 2020 04:05 pm ET
Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program
SEATTLE and VANCOUVER, British Columbia, Aug. 6, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2020 financial results and provided an update on the cytisinicline clinical development program.
Aug 06, 2020 04:05 pm ET
Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program
SEATTLE and VANCOUVER, British Columbia, Aug. 6, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced second quarter 2020 financial results and provided an update on the cytisinicline clinical development program.
Aug 04, 2020 09:00 am ET
Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering
SEATTLE and VANCOUVER, BC, Aug. 4, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 476,187 shares of its common stock at a price to the public of $10.50 per share. In addition, Achieve is offering to certain investors whose purchase of common stock would result in the investor, together with its affiliates, beneficially owning more than 9.99% of Achieve's com
Aug 04, 2020 09:00 am ET
Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering
SEATTLE and VANCOUVER, BC, Aug. 4, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 476,187 shares of its common stock at a price to the public of $10.50 per share. In addition, Achieve is offering to certain investors whose purchase of common stock would result in the investor, together with its affiliates, beneficially owning more than 9.99% of Achiev
Aug 03, 2020 04:00 pm ET
Achieve Life Sciences Announces Proposed Public Offering
SEATTLE and VANCOUVER, BC, Aug. 3, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock and, to certain investors whose purchase of common stock would result in the investor, together with its affiliates, beneficially owning more than 9.99% of Achieve's common stock following the completion of the offering, pr
Aug 03, 2020 04:00 pm ET
Achieve Life Sciences Announces Proposed Public Offering
SEATTLE and VANCOUVER, BC, Aug. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced a proposed underwritten public offering in which it intends to offer and sell shares of its common stock and, to certain investors whose purchase of common stock would result in the investor, together with its affiliates, beneficially owning more than 9.99% of Achieve's common stock following the completion of the offer
Jul 31, 2020 10:50 am ET
Thinking about buying stock in Achieve Life Sciences, Applied DNA Sciences, Delta Air Lines, Carnival Corp, or MGM Resorts?
NEW YORK, July 31, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACHV, APDN, DAL, CCL, and MGM.
Jul 31, 2020 08:30 am ET
Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications
SEATTLE and VANCOUVER, British Columbia, July 31, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the United States Patent and Trademark Office has granted Achieve a patent (US 2020/0172544 A1) on novel analogs of cytisinicline, a process for their preparation, and their use in the prevention or treatment of CNS and addictive disorders.
Jul 29, 2020 10:50 am ET
Thinking about buying stock in Achieve Life Sciences, Regulus Therapeutics, Exela Technologies, FireEye Inc, or Intel Corp?
NEW YORK, July 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACHV, RGLS, XELA, FEYE, and INTC.
Jul 28, 2020 05:30 am ET
Achieve Life Sciences to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
SEATTLE and VANCOUVER, British Columbia, July 28, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020. Company management will host a conference call and live webcast at 4:30 pm Eastern Time to report financial results and provide an update on the cytisinicline clinical development program.
Jul 28, 2020 05:30 am ET
Achieve Life Sciences to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
SEATTLE and VANCOUVER, British Columbia, July 28, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020. Company management will host a conference call and live webcast at 4:30 pm Eastern Time to report financial results and provide an update on the cytisinicline clinical development program.
Jul 22, 2020 10:35 am ET
Thinking about buying stock in Zomedica Pharmaceuticals, iBio Inc, Achieve Life Sciences, Intec Pharma, or Apple Inc?
NEW YORK, July 22, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, IBIO, ACHV, NTEC, and AAPL.
Jun 29, 2020 08:35 am ET
Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering
SEATTLE and VANCOUVER, BC, June 29, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 14,634,146 shares of common stock at a price of $0.41 per share in a registered direct offering, resulting in total gross proceeds of approximately $6 million, prior to deducting placement agent
Jun 29, 2020 08:35 am ET
Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering
SEATTLE and VANCOUVER, BC, June 29, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 14,634,146 shares of common stock at a price of $0.41 per share in a registered direct offering, resulting in total gross proceeds of approximately $6 million, prior to deducting placemen
May 14, 2020 07:30 am ET
Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program
SEATTLE and VANCOUVER, British Columbia, May 14, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2020 financial results and provided an update on the cytisinicline clinical development program.
May 14, 2020 07:30 am ET
Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program
SEATTLE and VANCOUVER, British Columbia, May 14, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced first quarter 2020 financial results and provided an update on the cytisinicline clinical development program.
May 05, 2020 08:00 am ET
Achieve Life Sciences to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 14, 2020
SEATTLE and VANCOUVER, British Columbia, May 5, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its first quarter 2020 financial results on Thursday, May 14, 2020. Company management will host a conference call and live webcast at 8:00 am Eastern Time to report financial results and provide an update on the cytisinicline clinical development program.
May 05, 2020 08:00 am ET
Achieve Life Sciences to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 14, 2020
SEATTLE and VANCOUVER, British Columbia, May 5, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its first quarter 2020 financial results on Thursday, May 14, 2020. Company management will host a conference call and live webcast at 8:00 am Eastern Time to report financial results and provide an update on the cytisinicline clinical development program.
Apr 30, 2020 04:50 pm ET
Achieve Life Sciences Announces Private Placement of $1.9 Million
SEATTLE and VANCOUVER, British Columbia, April 30, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into definitive agreements for a private placement of its securities for gross proceeds of approximately $1.9 million, prior to deducting placement agent commissions and estimated offering expenses.
Apr 30, 2020 04:50 pm ET
Achieve Life Sciences Announces Private Placement of $1.9 Million
SEATTLE and VANCOUVER, British Columbia, April 30, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has entered into definitive agreements for a private placement of its securities for gross proceeds of approximately $1.9 million, prior to deducting placement agent commissions and estimated offering expenses.
Apr 02, 2020 08:00 am ET
Seasoned Biotech Financial Executive, Jay M. Moyes, Joins Sera Prognostics
Sera Prognostics, Inc., The Pregnancy Company™, focused on improving maternal and neonatal health through innovative precision biomarker approaches, today announced the appointment of Jay M. Moyes as Chief Financial Officer. Mr. Moyes joins Sera...
Mar 13, 2020 08:00 am ET
Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program
SEATTLE and VANCOUVER, British Columbia, March 13, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced fourth quarter and year-end 2019 financial results and provided an update on the cytisinicline clinical development program.
Mar 12, 2020 05:30 am ET
Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
SEATTLE and VANCOUVER, British Columbia, March 12, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that additional analyses from the ORCA-1 Phase 2b trial will be presented today, Thursday, March 12th, at the SRNT Annual Meeting in New Orleans.
Mar 03, 2020 04:30 am ET
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2019 Financial Results and Host Conference Call and Webcast on March 13, 2020
SEATTLE and VANCOUVER, British Columbia, March 3, 2020 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced it that it will report its fourth quarter and year-end 2019 financial results on Friday, March 13, 2020. Company management will host a conference call and live webcast at 8:30 am Eastern Time to report financial results and provide an update on the cytisinicline clinical development program.
Dec 19, 2019 03:05 pm ET
Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
SEATTLE and VANCOUVER, British Columbia, Dec. 19, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of an underwritten public offering of units for gross proceeds of $13.8 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and estimated offering expenses.
Dec 17, 2019 12:06 pm ET
Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
SEATTLE and VANCOUVER, British Columbia, Dec. 17, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of units for gross proceeds of $12 million, prior to deducting underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on December 19, 2019, subject to customary closing conditions.
Dec 09, 2019 04:30 am ET
Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program
SEATTLE and VANCOUVER, British Columbia, Dec. 9, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced an update on the cytisinicline clinical development program.
Nov 06, 2019 05:30 am ET
Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program
SEATTLE and VANCOUVER, British Columbia, Nov. 6, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today provided an update on the cytisinicline clinical development program and announced third quarter 2019 financial results.
Nov 06, 2019 05:30 am ET
Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program
SEATTLE and VANCOUVER, British Columbia, Nov. 6, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today provided an update on the cytisinicline clinical development program and announced third quarter 2019 financial results.
Oct 31, 2019 05:30 am ET
Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019
SEATTLE and VANCOUVER, British Columbia, Oct. 31, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019. Company management will host a conference call and live webcast at 8:00am Eastern Time to report financial results and provide an update on the cytisinicline clinical development program.
Oct 31, 2019 05:30 am ET
Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019
SEATTLE and VANCOUVER, British Columbia, Oct. 31, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its third quarter 2019 financial results on Wednesday, November 6, 2019. Company management will host a conference call and live webcast at 8:00am Eastern Time to report financial results and provide an update on the cytisinicline clinical development program.
Oct 24, 2019 05:30 am ET
Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
SEATTLE, Wash. and VANCOUVER, British Columbia, Oct. 24, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that data from the Phase 2b ORCA-1 trial will be presented at the SRNT-O Inaugural Conference.  
Oct 24, 2019 05:30 am ET
Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
SEATTLE, Wash. and VANCOUVER, British Columbia, Oct. 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that data from the Phase 2b ORCA-1 trial will be presented at the SRNT-O Inaugural Conference.  
Sep 30, 2019 05:30 am ET
Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study
SEATTLE and VANCOUVER, British Columbia, Sept. 30, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced completion of their maximum tolerated dose (MTD) study. The results indicate a lack of dose-limiting toxicity as defined by protocol criteria even at the highest 30 mg single, oral dose of cytisinicline evaluated in the study.
Sep 30, 2019 05:30 am ET
Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study
SEATTLE and VANCOUVER, British Columbia, Sept. 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced completion of their maximum tolerated dose (MTD) study. The results indicate a lack of dose-limiting toxicity as defined by protocol criteria even at the highest 30 mg single, oral dose of cytisinicline evaluated in the study.
Sep 13, 2019 05:30 am ET
Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
SEATTLE and VANCOUVER, British Columbia, Sept. 13, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that two presentations featuring final data from the Phase 2b ORCA-1 trial will be conducted at the SRNT-E Annual Conference on Friday, September 13th in Oslo.
Sep 13, 2019 05:30 am ET
Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
SEATTLE and VANCOUVER, British Columbia, Sept. 13, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that two presentations featuring final data from the Phase 2b ORCA-1 trial will be conducted at the SRNT-E Annual Conference on Friday, September 13th in Oslo.
Sep 05, 2019 05:30 am ET
Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
SEATTLE and VANCOUVER, British Columbia, Sept. 5, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the Company will host its first investor day on Friday, September 20, 2019 in New York City. 
Sep 05, 2019 05:30 am ET
Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
SEATTLE and VANCOUVER, British Columbia, Sept. 5, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the Company will host its first investor day on Friday, September 20, 2019 in New York City. 
Sep 04, 2019 05:30 am ET
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia, Sept. 4, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Financial and Operating Officer, will present at two upcoming investor conferences.
Sep 04, 2019 05:30 am ET
Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
SEATTLE and VANCOUVER, British Columbia, Sept. 4, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Financial and Operating Officer, will present at two upcoming investor conferences.
Aug 08, 2019 05:39 pm ET
/C O R R E C T I O N -- Achieve Life Sciences, Inc./
In the news release, Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update, issued 08-Aug-2019 by Achieve Life Sciences, Inc. over PR Newswire, we are advised by the company that the column headers in the Consolidated Statements of Loss table have been updated. The complete, corrected release follows:
Aug 08, 2019 05:39 pm ET
/C O R R E C T I O N -- Achieve Life Sciences, Inc./
In the news release, Achieve Reports Financial Results for Second Quarter 2019 and Provides Cytisinicline Clinical Development Update, issued 08-Aug-2019 by Achieve Life Sciences, Inc. over PR Newswire, we are advised by the company that the column headers in the Consolidated Statements of Loss table have been updated. The complete, corrected release follows:
Jul 30, 2019 05:30 am ET
Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
SEATTLE and VANCOUVER, British Columbia, July 30, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its second quarter 2019 financial results on Thursday, August 8, 2019. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, the clinical development program, and a general corporate update.
Jul 30, 2019 05:30 am ET
Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
SEATTLE and VANCOUVER, British Columbia, July 30, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its second quarter 2019 financial results on Thursday, August 8, 2019. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, the clinical development program, and a general corporate update.
Jul 23, 2019 05:30 am ET
Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, July 23, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced it has extended its strategic collaboration with the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health (NIH). Under the extended collaboration, the NIH is funding and providing research efforts to conduct additional non-clinical studies as requested by the U.S. Food and Drug Administration (FDA) to be included in the cytisinicline New Drug Ap
Jun 03, 2019 04:05 pm ET
Achieve Receives $4.2 Million from Exercise of Warrants
SEATTLE and VANCOUVER, British Columbia, June 3, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it entered into an agreement with a single investor to exercise outstanding warrants that will provide an aggregate of $4.2 million in total proceeds. The proceeds from the warrant exercise would bring Achieve's pro-forma cash balance to approximately $13.9M as of March 31, 2019, based on its most recently reported financial resul
May 15, 2019 04:05 pm ET
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
SEATTLE and VANCOUVER, British Columbia, May 15, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced first quarter 2019 financial results.
May 15, 2019 04:05 pm ET
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
SEATTLE and VANCOUVER, British Columbia, May 15, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced first quarter 2019 financial results.
May 07, 2019 05:30 am ET
Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
SEATTLE and VANCOUVER, British Columbia, May 7, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its first quarter 2019 financial results on Wednesday, May 15, 2019. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, the clinical development program, and a general corporate update.
May 07, 2019 05:30 am ET
Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
SEATTLE and VANCOUVER, British Columbia, May 7, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its first quarter 2019 financial results on Wednesday, May 15, 2019. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, the clinical development program, and a general corporate update.
Apr 24, 2019 05:30 am ET
Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, April 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the last study visit for the last subject enrolled in the ORCA-1 trial occurred on April 23, 2019. ORCA-1 topline efficacy and safety data are expected to be announced by the end of the second quarter.
Apr 03, 2019 05:30 am ET
Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
SEATTLE, Wash. and VANCOUVER, British Columbia, April 3, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at HC Wainwright Global Life Sciences Conference being held at the Grosvenor House in Mayfair, London on Monday, April 8 at 11:50 a.m. BST.
Apr 02, 2019 05:30 am ET
Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the Data Safety Monitoring Committee (DSMC) met on March 28, 2019 to conduct its second and final safety review of the ORCA-1 Trial.
Mar 18, 2019 05:30 am ET
Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
SEATTLE and VANCOUVER, British Columbia, March 18, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at Oppenheimer's 29th Annual Healthcare Conference in New York on Wednesday, March 20 at 2:10 p.m. Eastern Time.
Mar 14, 2019 04:05 pm ET
Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
SEATTLE and VANCOUVER, British Columbia, March 14, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced fourth quarter and year-end 2018 financial results.
Mar 14, 2019 04:05 pm ET
Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
SEATTLE and VANCOUVER, British Columbia, March 14, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced fourth quarter and year-end 2018 financial results.
Mar 05, 2019 04:30 am ET
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019
SEATTLE and VANCOUVER, British Columbia, March 5, 2019 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its fourth quarter and year-end 2018 financial results on Thursday, March 14, 2019. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, the clinical development program, and a general corporate update.
Mar 05, 2019 04:30 am ET
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019
SEATTLE and VANCOUVER, British Columbia, March 5, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that it will report its fourth quarter and year-end 2018 financial results on Thursday, March 14, 2019. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, the clinical development program, and a general corporate update.
Feb 28, 2019 09:00 am ET
Predictive Technology Group Names Jay M. Moyes to Its Board of Directors
Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the...
Feb 25, 2019 08:31 am ET
Thinking about buying stock in Achieve Life Sciences, Kraft Heinz Co., Liquidia, Roku or Zillow?
NEW YORK, Feb. 25, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACHV, KHC, LQDA, ROKU, and Z.
Feb 22, 2019 04:30 am ET
Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual
SEATTLE and VANCOUVER, British Columbia, Feb. 22, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced final data from their Phase I/II multi-dose, pharmacokinetic and pharmacodynamics (PK/PD) clinical study of cytisinicline in smokers. Study results will be presented today, Friday, February 22nd, at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting in San Francisco.
Feb 20, 2019 04:30 am ET
Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, Feb. 20, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other addiction indications.
Dec 18, 2018 04:30 am ET
Achieve Announces Update on Cytisinicline Clinical Development Program
SEATTLE and VANCOUVER, British Columbia, Dec. 18, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided a clinical development update.
Nov 07, 2018 03:05 pm ET
Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update
SEATTLE and VANCOUVER, British Columbia, Nov. 7, 2018 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced third quarter 2018 financial results.
Nov 07, 2018 03:05 pm ET
Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update
SEATTLE and VANCOUVER, British Columbia, Nov. 7, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced third quarter 2018 financial results.
Oct 31, 2018 05:30 am ET
Achieve Life Sciences to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
SEATTLE, Wash. and VANCOUVER, British Columbia, Oct. 31, 2018 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline (cytisine) for smoking cessation, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, clinical development program, and general corporate update.
Oct 31, 2018 05:30 am ET
Achieve Life Sciences to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
SEATTLE, Wash. and VANCOUVER, British Columbia, Oct. 31, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline (cytisine) for smoking cessation, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, clinical development program, and general corporate update.
Oct 30, 2018 05:30 am ET
Achieve Life Sciences Announces Initiation of Phase 2b ORCA-1 Trial Evaluating Cytisinicline (cytisine) for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, Oct. 30, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced initiation of the Phase 2b ORCA-1 trial for smoking cessation.
Oct 01, 2018 09:05 am ET
Achieve Announces Pricing of $5.6 Million Registered Direct Offering
SEATTLE and VANCOUVER, British Columbia, Oct. 1, 2018 /CNW/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 1,789,258 shares of common stock at a price of $3.1445 per share in a registered direct offering, resulting in total gross proceeds of approximately $5.6 million. The Company also agreed to issue unregistered
Oct 01, 2018 09:05 am ET
Achieve Announces Pricing of $5.6 Million Registered Direct Offering
SEATTLE and VANCOUVER, British Columbia, Oct. 1, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 1,789,258 shares of common stock at a price of $3.1445 per share in a registered direct offering, resulting in total gross proceeds of approximately $5.6 million. The Company also agreed to issue unregi
Sep 27, 2018 05:30 am ET
Achieve Announces Results of Clinical Study Demonstrating Similar Bioavailability for a New Cytisine Formulation in Fed and Fasted Subjects
SEATTLE and VANCOUVER, British Columbia, Sept. 27, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of a new formulation for cytisine.
Sep 26, 2018 05:30 am ET
Achieve to Present at the Ladenburg Thalmann 2018 Healthcare Conference on October 2, 2018
SEATTLE and VANCOUVER, British Columbia, Sept. 26, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will present at the Ladenburg Thalmann 2018 Healthcare Conference being held Tuesday, October 2nd in New York City at the Sofitel Hotel New York.    
Sep 18, 2018 05:30 am ET
Achieve Announces Positive Cytisine Data Published in International Journal of Drug Policy
SEATTLE, Wash. and VANCOUVER, British Columbia, Sept. 18, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced the publication of new cytisine data from an independent observational study in the International Journal of Drug Policy. 
Sep 06, 2018 05:30 am ET
Achieve Life Sciences Announces Cytisine Data Presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Conference
SEATTLE and VANCOUVER, British Columbia, Sept. 6, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), today announced that cytisine data will be presented at the Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Conference , September 6-8th in Munich, Germany.  
Sep 05, 2018 05:30 am ET
Achieve to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 6, 2018
SEATTLE and VANCOUVER, British Columbia, Sept. 5, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that John Bencich, Chief Financial and Operations Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference being held September 4th to 6th at The St. Regis New York.    
Aug 08, 2018 04:05 pm ET
Achieve Reports Financial Results for Second Quarter 2018 and Provides Cytisine Clinical Development Update
SEATTLE and VANCOUVER, British Columbia, Aug. 8, 2018 /CNW/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today provided an update on the cytisine clinical development program and announced second quarter 2018 financial results.
Aug 08, 2018 04:05 pm ET
Achieve Reports Financial Results for Second Quarter 2018 and Provides Cytisine Clinical Development Update
SEATTLE and VANCOUVER, British Columbia, Aug. 8, 2018 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today provided an update on the cytisine clinical development program and announced second quarter 2018 financial results.
Aug 02, 2018 05:30 am ET
Achieve Life Sciences to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 8, 2018
SEATTLE and VANCOUVER, British Columbia, Aug. 2, 2018 /CNW/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that it will report its second quarter 2018 financial results on Wednesday, August 8, 2018. Company management will host a conference call and live webcast at 4:30pm Eastern Time to provide an overview of financial results, clinical development program, and general corporate update.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.